Program
Semaglutide
Also written as “semaglutide”, “Oral semaglutide” and “Semaglutide 2.4 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Alzheimer Disease, led by 11 companies.
Drug pageSemaglutide: every studyMany companies study it; this page follows only the 163 they lead. All 451 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 1518 open or running | phase 4since Jul 11, 2018 | Jun 11, 2008 | Dec 13, 2026phase 1 · NCT07225816 |
| CSPC Pharmaceutical Groupits history only | 20 open or running | phase 3since Nov 30, 2023 | Nov 30, 2023 | none ahead |
| Hangzhou Jiuyuan Gene Engineeringits history only | 21 open or running | phase 3since Feb 20, 2023 | Feb 20, 2023 | none ahead |
| Chengdu Brilliant Pharmaceuticalits history only | 11 open or running | phase 3since Mar 18, 2024 | Mar 18, 2024 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Jul 4, 2024 | Jul 4, 2024 | none ahead |
| Gila Therapeuticsits history only | 11 open or running | phase 4since Apr 17, 2026 | Apr 17, 2026 | May 2027phase 4 · NCT07728383 |
| Korea United Pharm.its history only | 11 open or running | phase 1since Oct 28, 2026 | Oct 28, 2026 | Nov 1, 2027phase 1 · NCT07935200 |
| Qilu Pharmaceutical | 11 open or running | phase 3since Jul 11, 2023 | Jul 11, 2023 | none ahead |
| Shanghai World Leader Pharmaceuticalits history only | 11 open or running | phase 1since Jan 28, 2026 | Jan 28, 2026 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 3since Dec 13, 2024 | Dec 13, 2024 | none ahead |
| Vivani Medicalits history only | 11 open or running | phase 1since Feb 10, 2026 | Feb 10, 2026 | Dec 2026phase 1 · NCT07430059 |
Also a collaborator on its studies: Celerion and Avance Clinical Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Qilu Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 11, 2023First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT05950516 · 478 planned · China
TargetBeta
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
The one study Qilu Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05950516Diabetes Mellitus, Type 2 · China | 3 | Not yet recruiting | Nov 24, 2024 | 478 |
How it is read
Names in the registry
- “semaglutide”, 83 entries
- “Semaglutide”, 66 entries
- “Oral semaglutide”, 11 entries
- “Semaglutide 2.4 mg”, 3 entries
- “Semaglutide J”, 3 entries
Codes read as this program: UI112, HD1916.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 94 studies
- Obesity, 42 studies
- Diabetes Mellitus, 17 studies
- Non-alcoholic Fatty Liver Disease, 4 studies
- Alzheimer Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.